Journal article
Model-based analysis of the relationship between pembrolizumab (MK-3475) exposure and efficacy in patients with advanced or metastatic melanoma.
-
Joseph, Richard Wayne
Mayo Clinic Cancer Center, Jacksonville, FL
-
Gangadhar, Tara C.
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA
-
Puzanov, Igor
Vanderbilt University Medical Center, Nashville, TN
-
Robert, Caroline
Gustave Roussy, Villejuif, France
-
Hamid, Omid
The Angeles Clinic and Research Institute, Los Angeles, CA
-
Dummer, Reinhard
University Hospital Zurich, Zurich, Switzerland
-
Ribas, Antoni
UCLA, Los Angeles, CA
-
Mehnert, Janice M.
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
-
Daud, Adil
UC San Francisco, San Francisco, CA
-
Celentano, Kellie Ann
Merck & Co., Inc., Kenilworth, NJ
-
Lindia, Jill Ann
Merck & Co., Inc., Kenilworth, NJ
-
Chatterjee, Manash Shankar
Merck & Co., Inc., Kenilworth, NJ
-
Turner, David C.
Merck & Co., Inc., Kenilworth, NJ
-
Mayawala, Kapil
Merck & Co., Inc., Kenilworth, NJ
-
Elassaiss-Schaap, Jeroen
PD-value B.V., Houten, Netherlands
-
de Alwis, Dinesh Prasad
Merck & Co., Inc., Kenilworth, NJ
-
Li, Xiaoyun Nicole
Merck & Co., Inc., Kenilworth, NJ
-
Ebbinghaus, Scot
Merck & Co., Inc., Kenilworth, NJ
-
Kang, Soonmo Peter
Merck & Co., Inc., Kenilworth, NJ
-
Kefford, Richard
Macquarie University and Westmead Hospital, Sydney, Australia
Show more…
Published in:
- Journal of Clinical Oncology. - American Society of Clinical Oncology (ASCO). - 2015, vol. 33, no. 15_suppl, p. 3068-3068
-
Language
-
-
Open access status
-
closed
-
Identifiers
-
-
Persistent URL
-
https://sonar.ch/global/documents/178907
Statistics
Document views: 14
File downloads: